1. Agency, E.M., 2013. Gilenya: EPAR: Product Information (updated July 2012). 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf.57〉.
2. Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks;Alroughani;Mult. Scler. Int.,2016
3. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology;Brinkmann;Pharmacol. Ther.,2007
4. Management of women with multiple sclerosis through pregnancy and after childbirth;Coyle;Ther. Adv. Neurol. Disord.,2016
5. Geissbühler, Y., Vile, J., Koren, G. et al., 2016. 〈http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146555/yvonne.geissbhler.cumulative.data.on.pregnancy.outcomes.after.exposure.to.html〉.